Plain-English translation of NCT06537843 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , cytarabine, and —given together—can help people with acute myeloid leukemia (AML), a serious blood cancer. The study focuses on people who either cannot receive standard chemotherapy because of age or health issues, or whose AML has come back after initial treatment. Researchers want to see if this three-drug combination is both safe and effective for these patients.
Standard chemotherapy doesn't work for everyone with AML—some patients are too frail or have other health conditions that make intense treatment risky, while others develop AML that resists the usual drugs. This trial explores whether this medication combination offers a better option for these difficult-to-treat cases.
You likely qualify if…
You likely don't qualify if…
You would take the three-drug medication combination as part of your treatment plan at a participating hospital. The trial involves regular visits to monitor how well the treatment is working and to check for any side effects. You will have blood tests and other standard medical checks to ensure the treatment is safe for you, and researchers will follow your health closely throughout the study period.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
Brazil